Most patients with early-stage lesions that are resectable generally tend to undergo surgery as their initial therapeutic approach, whereas those with advanced or unresectable cancers tend to be treated with radiotherapy (RT) alone or chemoradiotherapy (CRT), which hampered the comparison of the efficacy of RT alone with that of surgery combined with adjuvant RT. But some effort had been made to reflect the role of surgery in<unk> s. John Hunter from a 37-year-old man called John Burley on 24 October 1785. The<unk>  weighed over 4 kilograms and took twenty-five minutes to remove. The specimen currently resides in the Hunterian Museum at the Royal College of Surgeons of England Treatment may include the following: * Surgery Complete surgical resection, with adequate free margins, is currently the mainstay treatment for<unk> s. However elective treatment of the N0 neck region remains a controversial topic * Radiotherapy If a<unk>  is cancerous, Radiation Therapy may be necessary Fast neutron therapy has been used successfully to treat<unk> s, and has shown to be significantly more effective than photons in studies treating unresectable<unk> s. * Chemotherapy Currently little is known about the efficacy of chemotherapy in treating<unk> s. Chemotherapy, which plays an important role in systemic therapy, is generally reserved for the palliative treatment of symptomatic locally recurrent and/or metastatic disease that is not amenable to further surgery or radiation. Conventional chemotherapy regimens, such as cisplatin and 5-FU or CAP (cisplatin, doxorubicin, and cyclophosphamide) are still utilized as first-line therapy for patients with advanced lesions. Targeted Therapy - Due to the poor results with chemotherapy, it's urgent to explore novel therapeutic interventions for this disease. And great expectations have been put into individualized therapies: in particular, the EGF receptors family (EGFR and HER2), KIT and androgen receptors are the most commonly investigated molecular targets in SGCs. Their expression seems not to be linked to its pathogenetic role in the development of SGCs, but more to the histogenetic origin of the<unk>  cells. Various targeted agents, such as imatinib, cetuximab, gefitinib, trastuzumab, had been used for exploring new treatment for<unk> s, but on account of the rare incidence of<unk> s, the number of cases available on targeted therapy for analysis is relatively small.
Salivary gland tumour
Thyroid neoplasm
Thyroid lymphoma
Salivary gland fistula
Salivary gland disease
Salivary duct stricture
Thyroid cancer
Nasal glioma